Transferrin-targeted polymeric micelles Co-loaded with curcumin and paclitaxel: Efficient killing of paclitaxel-resistant cancer cells

Pharmaceutical Research

Volumn 31, Issue 8, 2014, Pages 1938-1945

  Abouzeid, Abraham H ^a   Patel, Niravkumar R ^a   Sarisozen, Can ^a   Torchilin, Vladimir P ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

combination treatment; curcumin; multi drug resistance (MDR); polymeric micelles; transferrin

Indexed keywords

CURCUMIN; MICELLE; PACLITAXEL; POLYMER; TRANSFERRIN;

CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; HUMAN; MICELLE; OVARY TUMOR; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL SURVIVAL; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICELLES; OVARIAN NEOPLASMS; PACLITAXEL; POLYMERS; TRANSFERRIN;

EID: 84893682873     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1295-x     Document Type: Article

References (38)

1. Hofmann M, Guschel M, Bernd A, Bereiter-Hahn J, Kaufmann R, Tandi C, et al. Lowering of tumor interstitial fluid pressure reduces tumor cell proliferation in a xenograft tumor model. Neoplasia. 2006;8(2):89-95.
2. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219-34.
3. Borg AG, Burgess R, Green LM, Scheper RJ, Liu Yin JA. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Haematol. 1998;103(4):1083-91.
4. Gregorcyk S, Kang Y, Brandt D, Kolm P, Singer G, Perry RR. Best clinical research paper p-glycoprotein expression as a predictor of breast cancer recurrence. Eur J Surg Oncol: J Eur Soc Surg Oncol Br Assoc Surg Oncol. 1996;22(1):121.
5. Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JGM, Wiemer EAC, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res. 2003;9(2):827-36.
6. Materna V, Pleger J, Hoffmann U, Lage H. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol. 2004;94(1):152-60.
7. Arts HJG, Katsaros D, de Vries EGE, Massobrio M, Genta F, Danese S, et al. Drug Resistance-associated Markers P-Glycoprotein, Multidrug Resistance-associated Protein 1, Multidrug Resistance-associated Protein 2, and Lung Resistance Protein as Prognostic Factors in Ovarian Carcinoma. Clin Cancer Res. 1999;5(10):2798-805.
8. Chan HSL, Haddad G, DeBoer G, Ling V, Grogan TM. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst. 1997;89(22):1706-15.
9. Kawasaki M, Nakanishi Y, Kuwano K, Takayama K, Kiyohara C, Hara N. Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer. 1998;34(9):1352-7.
10. Yeh JJ, Hsu NY, Hsu WH, Tsai CH, Lin CC, Liang JA. Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer. Lung. 2005;183(3):177-83.
11. Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta (BBA) Gene Regul Mech. 2010;1799(10-12):775-87.
12. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 2003;22(1):90-7.
13. Thévenod F, Friedmann JM, Katsen AD, Hauser IA. Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-κB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis. J Biol Chem. 2000;275(3):1887-96.
14. Zhou G, Kuo MT. NF-κB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J Biol Chem. 1997;272(24):15174-83.
15. Ogretmen B, Safa AR. Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-κB/p65 and c-Fos transcription factors and their interaction with the CAAT region†. Biochemistry. 1999;38(7):2189-99.
16. Macus Tien Kuo ZL, Wei Y, Lin-Lee Y-c, Tatebe S, Mills GB, Unate H. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-κB signaling. Oncogene. 2002;21(13):1948-54.
17. Sreekanth CN, Bava SV, Sreekumar E, Anto RJ. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene. 2011;30(28):3139-52.
18. Bava SV, Sreekanth CN, Thulasidasan AK, Anto NP, Cheriyan VT, Puliyappadamba VT, et al. Akt is upstream and MAPKs are downstream of NF-kappaB in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism. Int J Biochem Cell Biol. 2011;43(3):331-41.
19. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MNVR. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci. 2009;37(3-4):223-30.
20. Kakkar V, Muppu SK, Chopra K, Kaur IP. Curcumin loaded solid lipid nanoparticles: an efficient formulation approach for cerebral ischemic reperfusion injury in rats. Eur J Pharm Biopharm.
21. Gangwar RK, Dhumale VA, Kumari D, Nakate UT, Gosavi SW, Sharma RB, et al. Conjugation of curcumin with PVP capped gold nanoparticles for improving bioavailability. Mater Sci Eng C. 2012;32(8):2659-63.
22. Akhtar F, Rizvi MMA, Kar SK. Oral delivery of curcumin bound to chitosan nanoparticles cured Plasmodium yoelii infected mice. Biotechnol Adv. 2012;30(1):310-20.
23. Sahu A, Bora U, Kasoju N, Goswami P. Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells. Acta Biomater. 2008;4(6):1752-61.
24. Patel NR, Rathi A, Mongayt D, Torchilin VP. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int J Pharm. 2011;416(1):296-9.
25. Torchilin VP. Targeted polymeric micelles for delivery of poorly soluble drugs. CMLS Cell Mol Life Sci. 2004;61(19-20):2549-59.
26. Wang J, Tian S, Petros RA, Napier ME, DeSimone JM. The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies. J Am Chem Soc. 2010;132(32):11306-13.
27. Indira Chandran V, Matesic L, Locke JM, Skropeta D, Ranson M, Vine KL. Anti-cancer activity of an acid-labile N-alkylisatin conjugate targeting the transferrin receptor. Cancer Lett. 2012;316(2):151-6.
28. Xu S, Liu Y, Tai H-C, Zhu J, Ding H, Lee RJ. Synthesis of transferrin (Tf) conjugated liposomes via Staudinger ligation. Int J Pharm. 2011;404(1-2):205-10.
29. Pang Z, Gao H, Yu Y, Chen J, Guo L, Ren J, et al. Brain delivery and cellular internalization mechanisms for transferrin conjugated biodegradable polymersomes. Int J Pharm. 2011;415(1-2):284-92.
30. Hong M, Zhu S, Jiang Y, Tang G, Pei Y. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. J Control Release. 2009;133(2):96-102.
31. Daniels TR, Bernabeu E, Rodriguez JA, Patel S, Kozman M, Chiappetta DA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2012;1820(3):291-317.
32. Gomme PT, McCann KB, Bertolini J. Transferrin: structure, function and potential therapeutic actions. Drug Discov Today. 2005;10(4):267-73.
33. Kobayashi T, Ishida T, Okada Y, Ise S, Harashima H, Kiwada H. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int J Pharm. 2007;329(1-2):94-102.
34. Torchilin VP, Levchenko TS, Lukyanov AN, Khaw BA, Klibanov AL, Rammohan R, et al. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim Biophys Acta (BBA) Biomembr. 2001;1511(2):397-411.
35. Sawant RR, Sawant RM, Torchilin VP. Mixed PEG-PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: improved drug solubilization and enhanced in vitro cytotoxicity. Eur J Pharm Biopharm Off J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2008;70(1):51-7.
36. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci U S A. 2003;100(10):6039-44.
37. Chou TCTP. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul. 1984;22:27-55.
38. Dicko A, Mayer LD, Tardi PG. Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo. Expert Opin Drug Deliv. 2010;7(12):1329-41.